Inhibition of Experimental Proliferative Vitreoretinopathy by Retroviral Vector-mediated Transfer of Suicide Gene: Can Proliferative Vitreoretinopathy be a Target of Gene Therapy?
References (26)
- et al.
Inhibition of intraocular proliferations with intravitreal corticosteroids
Am J Ophthalmol
(1980) - et al.
The role of cellular proliferation in an experimental model of massive periretinal proliferation
Am J Ophthalmol
(1982) - et al.
Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information
Virology
(1980) - et al.
Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS
Am J Ophthalmol
(1987) - et al.
Treatment of cytomegalovirus retinitis with ganciclovir
Ophthalmology
(1987) The classification of retinal detachment with proliferative vitreoretinopathy
Ophthalmology
(1983)- et al.
Pathobiology of proliferative vitreoretinopathy
Surgery for proliferative vitreoretinopathy
- et al.
The mechanism of action of drugs for the treatment of vitreoretinal scarring
- et al.
Human gene therapy
Annu Rev Biochem
(1993)
Human gene therapy
Science
Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes. Paradigm for a prospective cancer control strategy
Cancer Res
Selective elimination of recombinant genes in vivo with a suicide retroviral vector
New Biol
Cited by (60)
Channelrhodopsins: Visual regeneration and neural activation by a light switch
2013, New BiotechnologyCitation Excerpt :This technique involves using a recombinant virus containing the ChR2 gene, which is injected into a specific region on the gene and hence expressed either selectively or broadly, depending on the aim. A multitude of viral vectors, including adenoviruses [26], adenoassociated viruses (AAV) [27], retroviruses [28] and lentiviruses [29,30], have been used experimentally. By using viral vectors, precise cells can be targeted by other means apart from using specific promoters.
Proliferative vitreoretinopathy
2012, Retina Fifth EditionProliferative Vitreoretinopathy
2005, Retina: Fourth EditionPosterior Segment Trauma: Open Globe
2005, Retina: Fourth EditionThe Mechanism of Action of Drugs for The Treatment of Vitreoretinal Scarring
2005, Retina: Fourth EditionA randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy
2004, OphthalmologyCitation Excerpt :Enhancing the specificity of treatment regimens to target the cellular or molecular components of the PVR process is a further potential future strategy. Gene transfer has been demonstrated to reduce experimental PVR29 and could also provide a more targeted approach to clinical disease. Recently, in vivo gene transfer–induced overexpression of an attenuated platelet-derived growth factor receptor has been shown to reduce experimental PVR,30 and such an approach, which combines enhanced specificity with a more prolonged therapeutic effect, is an attractive future option.
Supported in part by grants EY02061 and EY03040 from the National Institutes of Health, Bethesda, Maryland. The Department of Ophthalmology is a recipient of an award from Research to Prevent Blindness, Inc, New York, New York, and Dr. Sakamoto is a recipient of a foreign scholarship award from Research to Prevent Blindness and from the Nippon Eye Bank Association, Tokyo, Japan.